The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...

AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...

Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer ...

The FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients ...

The innovative GO chip, developed at the University of Michigan, represents a significant leap in lung cancer treatment by ...

The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a ...

The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly ...

Regeneron Pharmaceuticals, announced that FDA accepted its resubmitted Biologics License Application for odronextamab, a ...

The CheckMate -816 trial shows nivolumab plus platinum-doublet chemotherapy significantly improves overall survival in ...

Francis Medical, developing water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced the completion of patient enrollment and initial treatments in its VAPOR 2 ...

In this interview with Dr. Maria de Miguel, we explore the transformative potential of Antibody-Drug Conjugates (ADCs) in ...

AI is evolving fast and life sciences is feeling the impact. In 2025, its role will expand even further, driving efficiencies and accelerating discoveries. The industry has already seen what AI can do ...